Publications

Detailed Information

MYC quantitation in cell-free plasma DNA by real-time PCR for gastric cancer diagnosis

DC Field Value Language
dc.contributor.authorPark, Kyoung Un-
dc.contributor.authorLee, Hee Eun-
dc.contributor.authorPark, Do Joong-
dc.contributor.authorJung, Eun Ji-
dc.contributor.authorKim, Hyung-Ho-
dc.contributor.authorKim, Woo Ho-
dc.contributor.authorLee, Hye Seung-
dc.contributor.authorChoe, Gheeyoung-
dc.contributor.authorSong, Junghan-
dc.date.accessioned2012-05-31T08:18:31Z-
dc.date.available2012-05-31T08:18:31Z-
dc.date.issued2009-05-
dc.identifier.citationCLINICAL CHEMISTRY AND LABORATORY MEDICINE; Vol.47 5; 530-536ko_KR
dc.identifier.issn1434-6621-
dc.identifier.urihttps://hdl.handle.net/10371/76706-
dc.description.abstractBackground: Detection of tumor-associated genetic alterations in plasma of cancer patients has recently been suggested to be an accurate method for detecting early or recurrent cancer. Methods: We performed quantitative real-time PCR for MYC and GAPDH in tissue and plasma samples of 57 patients with gastric cancer and in plasma of 79 cancer-free individuals. We also performed two-color MYC fluorescence in situ hybridization (FISH) in tissue from the 57 patients with gastric cancer. Results: The tissue MYC/GAPDH ratio by real-time PCR was significantly correlated with MYC status by FISH (p<0.001). The mean ratio of plasma MYC/GAPDH was 5.226+/-3.578 (range: 1.25-18.35) in gastric cancer patients, and 2.436+/-0.881 (range: 1.00-5.00) in the healthy volunteers (p<0.001). We used receiver-operating characteristics (ROC) curve analysis to select two optimal plasma MYC/GAPDH cut-offs of 2.725 and 5.225. The sensitivity and specificity were 75.4% and 76.9% at 2.725, 38.6% and 100% at 5.225, respectively. The plasma MYC/GAPDH ratio from cancer patients was significantly correlated with the tissue MYC/GAPDH ratio (p=0.009), and tissue MYC status by FISH (p=0.024). Conclusions: These findings suggest that the plasma MYC/GAPDH ratio, as determined by real-time PCR, may be an alternative non-invasive approach for detecting gastric cancer. Clin Chem Lab Med 2009; 47:530-6.ko_KR
dc.language.isoenko_KR
dc.publisherWALTER DE GRUYTER & COko_KR
dc.subjectMYCko_KR
dc.subjectplasma DNAko_KR
dc.subjectstomach cancerko_KR
dc.subjectreal-time PCRko_KR
dc.titleMYC quantitation in cell-free plasma DNA by real-time PCR for gastric cancer diagnosisko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor박경운-
dc.contributor.AlternativeAuthor이희은-
dc.contributor.AlternativeAuthor박도중-
dc.contributor.AlternativeAuthor정은지-
dc.contributor.AlternativeAuthor송정한-
dc.contributor.AlternativeAuthor김형호-
dc.contributor.AlternativeAuthor최기영-
dc.contributor.AlternativeAuthor김우호-
dc.contributor.AlternativeAuthor이혜승-
dc.identifier.doi10.1515/CCLM.2009.126-
dc.citation.journaltitleCLINICAL CHEMISTRY AND LABORATORY MEDICINE-
dc.description.citedreferenceKim MA, 2007, HUM PATHOL, V38, P1386, DOI 10.1016/j.humpath.2007.02.005-
dc.description.citedreferenceSai S, 2007, ANTICANCER RES, V27, P2747-
dc.description.citedreferenceMitsui F, 2007, MODERN PATHOL, V20, P622, DOI 10.1038/modpathol.3800777-
dc.description.citedreferenceVita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015-
dc.description.citedreferenceCorzo C, 2006, CANCER GENET CYTOGEN, V165, P151, DOI 10.1016/j.cancergencyto.2005.08.013-
dc.description.citedreferenceCrew KD, 2006, WORLD J GASTROENTERO, V12, P354-
dc.description.citedreferenceCalcagno DQ, 2005, ANTICANCER RES, V25, P4069-
dc.description.citedreferenceGotoh T, 2005, J CLIN ONCOL, V23, P5205, DOI 10.1200/JCO.2005.02.014-
dc.description.citedreferenceTse C, 2005, CLIN CHEM, V51, P1093, DOI 10.1373/clinchem.2004.044305-
dc.description.citedreferenceKindich R, 2005, CLIN CHEM, V51, P649, DOI 10.1373/clinchem.2004.045013-
dc.description.citedreferenceLee TL, 2002, CLIN CANCER RES, V8, P1761-
dc.description.citedreferenceUsadel H, 2002, CANCER RES, V62, P371-
dc.description.citedreference*AM JOINT COMM CAN, 2002, AJCC CANC STAG MAN, P99-
dc.description.citedreferenceLivak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262-
dc.description.citedreferenceLee HS, 2001, CANCER, V92, P1427-
dc.description.citedreferenceLo YMD, 2001, CLIN CANCER RES, V7, P1856-
dc.description.citedreferenceKoo SH, 2000, CANCER GENET CYTOGEN, V117, P97-
dc.description.citedreferenceAALTONEN LA, 2000, INT AGENCY RES CANC, P37-
dc.description.citedreferenceCastells A, 1999, J CLIN ONCOL, V17, P578-
dc.description.citedreferenceHara T, 1998, LAB INVEST, V78, P1143-
dc.description.citedreferenceLandis SH, 1998, CA-CANCER J CLIN, V48, P6-
dc.description.citedreferenceSuzuki S, 1997, J SURG ONCOL, V66, P173-
dc.description.citedreferenceNawroz H, 1996, NAT MED, V2, P1035-
dc.description.citedreferenceHenriksson M, 1996, ADV CANCER RES, V68, P109-
dc.description.citedreferencePARK JG, 1990, CANCER RES, V50, P2773-
dc.description.citedreferenceSTROUN M, 1989, ONCOLOGY, V46, P318-
dc.description.citedreferenceLAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31-
dc.description.tc3-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share